Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Albert Einstein Medical Center
mi
from
Bronx, NY
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Albert Einstein Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Monter Cancer Center
mi
from
Lake Success, NY
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Monter Cancer Center
mi
from
Lake Success, NY
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Blumenthal Cancer Center
mi
from
Charlotte, NC
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Blumenthal Cancer Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Cancer Centers of North Carolina
mi
from
Raleigh, NC
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Cancer Centers of North Carolina
mi
from
Raleigh, NC
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Oncology Hematology Care, Inc.
mi
from
Blue Ash, OH
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Oncology Hematology Care, Inc.
mi
from
Blue Ash, OH
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
The Mark H. Zangmeister Center
mi
from
Columbus, OH
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
The Mark H. Zangmeister Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Oregon Health and Science University
mi
from
Portland, OR
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
The West Clinic, PC
mi
from
Memphis, TN
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Texas Oncology, PA
mi
from
Dallas, TX
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Texas Oncology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Utah Cancer Specialists
mi
from
Salt Lake City, UT
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Utah Cancer Specialists
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Virginia Oncology Associates
mi
from
Norfolk, VA
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Virginia Cancer Institute
mi
from
Richmond, VA
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Virginia Cancer Institute
mi
from
Richmond, VA
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
SUNY Upstate Medical University
mi
from
Syracuse, NY
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Hot Springs, AR
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Jonesboro, AR
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Greenbrae, CA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Colorado Springs, CO
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Bonita Springs, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Bonita Springs, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Bradenton, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Cape Coral, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Cape Coral, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
mi
from
Ft. Meyers, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
mi
from
Ft. Meyers, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Naples, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Port Charlotte, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Sarasota, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Venice, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Venice, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Atlanta, GA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Augusta, GA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Macon, GA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Macon, GA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Marietta, GA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Chicago, IL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Billings, MT
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Billings, MT
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Albany, NY
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
East Setauket, NY
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
East Setauket, NY
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Kettering, OH
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Kettering, OH
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Greenville, SC
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Nashville, TN
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Dallas, TX
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Ft. Worth, TX
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Ft. Worth, TX
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Tyler, TX
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Spokane, WA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Marshfield, WI
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Marshfield, WI
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
mi
from
Belo Horizonte,
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
mi
from
Belo Horizonte,
Click here to add this to my saved trials
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Tucson, AZ
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials